
Vaxcyte (PCVX) Stock Forecast & Price Target
Vaxcyte (PCVX) Analyst Ratings
Bulls say
Vaxcyte is a clinical-stage biotech company that has a strong pipeline of potential vaccine candidates addressing unmet needs in adult and pediatric indications with high market opportunities. With positive Phase 1/2 data and fast-track designation for their lead candidate VAX-24 for pneumococcal disease, as well as updates on their other vaccine programs, the company is on track for pivotal Phase 3 data in 2026. This, along with their established financial backing, makes Vaxcyte a top pick for 2026 with a potentially transformational 18 months ahead, positioning their stock for growth in the years to come.
Bears say
Vaxcyte is a clinical-stage vaccine company with a strong product pipeline, including VAX-31, VAX-24, VAX-XL, VAX-A1, and VAX-GI. However, the company may face challenges in bringing these vaccines to market, with the earliest potential market entry not expected until 2027 and projected peak penetration of 60% in newborns. Additionally, there are uncertainties around pricing and potential serotype replacement. These factors lead to a negative outlook for Vaxcyte's stock and a valuation primarily relying on VAX-24 with a discounted cash flow analysis assuming a 14.5% discount rate and 1.0% terminal growth rate.
This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.
Vaxcyte (PCVX) Analyst Forecast & Price Prediction
Start investing in Vaxcyte (PCVX)
Order type
Buy in
Order amount
Est. shares
0 shares